Difluprednate Emulsion
Product Images NDC 62332-750

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Difluprednate (NDC 62332-750). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Difluprednate-bottle-label (Difluprednate Bottle Label)

This is a medication containing difluprednate 0.05%. It is an ophthalmic emulsion used for specific eye conditions. Directions for use and storage information can be found in the package insert. The product is manufactured by Alembic Pharmaceuticals, Inc. in India and distributed in the USA. The NDC number is 62332-750-05. Be sure to check the Lot number and expiration date before use.*

FDA Label Image

Difluprednate-carton (Difluprednate Carton)

This is a description of Difluprednate Ophthalmic Emulsion 0.05%, a medication used for topical eye treatment. It is manufactured by Alembic Pharmaceuticals and comes in a 5mL bottle. The active ingredient is difluprednate 0.05%, and it also contains various inactive ingredients. The prescription should be followed as per the package insert. The product should be stored at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Once opened, it can be used until the expiration date indicated on the bottle. It is important to keep the medication out of the reach of children.*

FDA Label Image

Difluprednate-figure-1 (Difluprednate Figure 1)

This text provides data on the percentage of subjects with anterior chamber cells clearing (cell count = 0) on Day 8 and Day 15. It compares the results between the Difluprednate ophthalmic emulsion group (n=107) and the Placebo group (n=220). The percentage of subjects with clear anterior chamber cells on Day 8 is 2% for the Difluprednate group and 12% for the Placebo group. There is a statistically significant difference indicated by * P<0.05.*

FDA Label Image

Difluprednate-figure-2 (Difluprednate Figure 2)

This information provides data on the percentage of subjects who were pain-free after using difluprednate ophthalmic emulsion four times a day. The study involved 107 participants treated with difluprednate and 220 participants receiving a placebo. The results show a statistically significant difference at days 3, 8, and 15, where the treatment group had a higher percentage of pain-free subjects compared to the placebo group.*

FDA Label Image

Difluprednate-structure (Difluprednate Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.